{"ticker": {"uuid": "5021986b-8afe-404f-9dfe-03dd60f3db10", "symbol": "QURE", "name": "Uniqure NV", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "uniQure starts $150M share sale, with $22.5M extra option", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQLVZuLWtBOUxpZS0wN2lPSkt4aFJaMFl6bDlXbjdSX05OVzdSZlYyUnY4LTJTR2xjQUlGRlR5eUsyMnUyTmU2Y0w2VjhFcXpISE9VTklabkpHc1F1X05BaXpXamh2WlpnWDRPRDB2ZEhIdkR0bDBJTjNvWFhQcmR4YUhTWmQzOE9yYi1yMzFscUJwZ1Ezd3RJLUxQWndnX0RUSmp3?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T20:03:47+00:00", "published_display": "22 Jun 2026 20:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "uniQure (QURE) CEO sells 206,100 shares and exercises stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxONzdteHo0QUw4b1VGYU1Ha1VYVEt4dHJSTmM2U1luT3BrVTdQOTF0VkNSNUhSbjQwTEtiNTdyeFZ2QnFsd29XRUdnN0N6V0hQWlpaU0JndUtTYnBsMzRmWmRUdmVDVi1qM1lTUDdOVVRJalVjTmNXbjhPbWxwTElMUGNxWUFZc1UtdTJSZXl4UU1JQ3ZnUXpxbDdxWW1fY2Q1YzZvbGkydjFMdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T12:31:27+00:00", "published_display": "22 Jun 2026 12:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "uniQure (QURE) director exercises 11,685 options, sells shares under 10b5-1", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPMjM1UnQ2UXdRbmtwLTBaZXhfUVBaMGNkYzU5OVc4dU9RVXdFeWFBTG0yTFBrclBrQ1MwLV9EMFlJWGZTR0dMTUl1MngwYkNwajFOVWNrQnVhSklnZ2g5QVh1aFZ6OHFfdHlrOHIzSnoxOGM2WjI0RHNROGg0VGpJMHVrY245c0ItdmZhWDRUT0xWU0lORzA2WkN1YTZqQndGN3BheWtuS0dTdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T12:05:31+00:00", "published_display": "22 Jun 2026 12:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "uniQure (QURE) Secures FDA Reversal for Huntington's Disease Gen", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNdkdiMjdkV2Y4UDI4eHBmVVE0RmEwQ1U5Zjg3dnF6ekNNdXNZWDlFckZ0aGR6RTJ3N3AwbjBxY2ZYRjQ2MG9BOWV3c2gtYjdzelZsbERONHRVQ2ZKRFVZR3ZiTlViQlpHb0lBMWVfak5pOHlzenBmSGxmWTZHU2pvR1VJQ3JsVW9fMTQ2UnVHdHpsNGxsY0YyaVFRQnhmNlNRUzJOQ3h0LUVUZDRySFE?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-22T11:29:05+00:00", "published_display": "22 Jun 2026 11:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "uniQure (QURE) director Jack Kaye sells shares after exercising stock options", "summary": "uniQure N.V. director Jack Kaye exercised stock options for 5,295 ordinary shares at $31.71 each and subsequently sold all of them in the open market for a weighted average price of $42.57. These transactions, which occurred on June 17, 2026, were conducted under a pre-arranged R", "url": "https://www.stocktitan.net/sec-filings/QURE/form-4-uni-qure-n-v-insider-trading-activity-744ddceff83c.html", "source_name": "Stock Titan", "published_at": "2026-06-22T12:09:37", "published_display": "22 Jun 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "uniQure (QURE) shows mixed but promising early AMT-260 MTLE results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPTExaUWhqd2lsVDFDZ3FBRU9hSVE4c0o1Vlhnbjc1ZVRoQ2Q0cHNYMXVONHIwS3VVQ1NLZDF2ZWl5d2pDc094YXFpM0RuV3hvRmlZUVZ2ajBtbUxIbVZtLWU1S0oyTm9FSmxwWTZVSFhaeDlrT0oyYXZnQTJIS0lBdW9BWEwzVHZMdEFPM2pCQ2dZbzdGZjMwYTBsVUYwLUpNZHRr?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T10:50:13+00:00", "published_display": "22 Jun 2026 10:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "uniQure reports preliminary AMT-260 Phase I/IIa low-dose results; 3 of 6 patients show 79\u2013100% seizure reduction", "summary": "uniQure announced preliminary six-month data from its AMT-260 Phase I/IIa trial, revealing that three out of six low-dose patients experienced significant seizure reductions of 79\u2013100%. The treatment was generally well-tolerated, with no serious adverse events reported and no imm", "url": "https://www.tradingview.com/news/tradingview:6ac619a43cdc0:0-uniqure-reports-preliminary-amt-260-phase-i-iia-low-dose-results-3-of-6-patients-show-79-100-seizure-reduction/", "source_name": "TradingView", "published_at": "2026-06-22T11:09:37", "published_display": "22 Jun 2026 11:09", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "QURE Stock Just Shot Up 8% - uniQure\u2019s Much-Talked-About Huntington\u2019s Disease Therapy Gets A UK Boost", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxNY0tPbUFINEhwMU9PRUNMMEVMNUF5UmplQTdhWTUtSU1hVnRQUUhzaklpdU5xdkN5aW9tdWpVR2EySDctYm5WQnJTc0NlTVdiOE93bkkyUzBVbERSZWoxdlhwY1NXRUVLVEVGbUo2VTg3VnFqU0d5U0cwOEJ2dFhpeTJxUlJ5clpNVldhbGc4SVdtS3dYUDlwalJoVGNtYVV4QXJ3NE9YamlzMzFpSlp0c24ydjIyRDJDamstRDdQM3pwc0NXZjh0aTNOZzI?oc=5", "source_name": "Stocktwits", "published_at": "2026-06-21T07:10:37+00:00", "published_display": "21 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "uniQure (QURE) Stock Could Be 12% Undervalued After FDA Backs AMT 130 Filing Path", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-20T13:28:27+00:00", "published_display": "20 Jun 2026 13:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "QURE Soars as FDA Backs AMT-130 Data for Accelerated Approval", "summary": "uniQure (QURE) saw its shares jump significantly after the FDA indicated that three-year data from its phase I/II study on AMT-130, a gene therapy for Huntington's disease, could support an accelerated approval BLA. This news provides relief to investors following a previous regu", "url": "https://www.tradingview.com/news/zacks:2dd42ff47094b:0-qure-soars-as-fda-backs-amt-130-data-for-accelerated-approval/", "source_name": "TradingView", "published_at": "2026-06-19T18:40:52", "published_display": "19 Jun 2026 18:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/uniqure-announces-preliminary-data-first-110500802.html", "source_name": "GlobeNewswire", "published_at": "2026-06-19T11:05:00+00:00", "published_display": "19 Jun 2026 11:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "uniQure (QURE) Stock Sees Fair Value Lift As AMT 130 BLA Plans Rework Risk", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNbTZNSVR5M05lNllZY1RYMnhtcVdTbVNMZUpURjFJWTJnNE85NHEyR0xpQmJLd2I3Z3daNV9xNEMxdE1mSTY2RGxlXzVzYjA2WXVhXzNPaEZKZEsyVEFUUDd0UHV1TDRZY1JBalFVQUNMakxKUER1ZjNNTTVjWnU5TmNJMUZld3RzdTAxT1JQVm8ySi04eDRQYw?oc=5", "source_name": "Market source", "published_at": "2026-06-19T10:11:19+00:00", "published_display": "19 Jun 2026 10:11", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "uniQure\u2019s epilepsy gene therapy showed seizure drops in 3 patients", "summary": "uniQure announced preliminary six-month data from the first, low-dose cohort of its Phase I/IIa trial for AMT-260, an investigational gene therapy for refractory mesial temporal lobe epilepsy. Three of six patients showed significant reductions (79%-100%) in disabling seizures, w", "url": "https://www.stocktitan.net/news/QURE/uni-qure-announces-preliminary-data-on-the-first-cohort-in-the-phase-z3qytxeiakcc.html", "source_name": "Stock Titan", "published_at": "2026-06-19T11:04:46", "published_display": "19 Jun 2026 11:04", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "uniQure Announces Preliminary Data on the First Cohort in", "summary": "uniQure announced preliminary six-month data from the first cohort of its Phase I/IIa trial for AMT-260, an investigational gene therapy for refractory mesial temporal lobe epilepsy. Three of six patients in the low-dose cohort experienced significant reductions in seizures, with", "url": "https://www.globenewswire.com/news-release/2026/06/19/3314701/0/en/uniqure-announces-preliminary-data-on-the-first-cohort-in-the-phase-i-iia-clinical-trial-of-amt-260-in-refractory-mesial-temporal-lobe-epilepsy.html", "source_name": "GlobeNewswire", "published_at": "2026-06-19T11:04:46", "published_display": "19 Jun 2026 11:04", "sentiment": "positive", "sentiment_pct": 65, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "uniQure (QURE) Stock Could Be 49% Undervalued After FDA AMT 130 Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxQN05oSVcxSkZDczlPN19CSTI0dzRCX1hRVVFmYmlVRGFhc09OTXFsRktZRUlfNWNWR1hKUWVyNGVqZlBDREl2Z3J6bnZCZVRLdzktRlZnWnVZaU5NWDhKWXFSb2ttUmJ0TVN6RHdVUGptb0xBZnlTb25rNnQwTG94ZHQyakdRMExjV2h1TmF2aGdnSEFBU1pN?oc=5", "source_name": "Market source", "published_at": "2026-06-19T06:15:10+00:00", "published_display": "19 Jun 2026 06:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "uniQure (QURE) Is Up 67.9% After FDA Backs AMT-130 Data For Accelerated Approval Path", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/uniqure-qure-67-9-fda-050753380.html", "source_name": "Simply Wall St.", "published_at": "2026-06-19T05:07:53+00:00", "published_display": "19 Jun 2026 05:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Quick Look at Today's Ratings for UniQure NV(QURE.US), With a Forecast Between $46 to $70", "summary": "This article provides an overview of recent analyst ratings for uniQure NV (QURE.US), highlighting that analysts have set price targets ranging from $46 to $70. The consensus among analysts suggests a positive outlook for the company's stock performance.", "url": "https://www.moomoo.com/news/post/71734507/a-quick-look-at-today-s-ratings-for-uniqure-nv", "source_name": "Moomoo", "published_at": "2026-06-19T00:10:39", "published_display": "19 Jun 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "uniQure N.V. (NASDAQ: QURE) insider sells 164,429 shares across June filings", "summary": "uniQure N.V. (NASDAQ: QURE) insider Matthew C. Kapusta has reported planned and completed sales of 164,429 ordinary shares across various June filings. This includes recent market sales on June 17 and June 18, 2026, totaling over $7.2 million, as well as scheduled dispositions of", "url": "https://www.stocktitan.net/sec-filings/QURE/144-uni-qure-n-v-sec-filing-fe11e58baabc.html", "source_name": "Stock Titan", "published_at": "2026-06-18T21:39:18", "published_display": "18 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "uniQure Stock Looks Drastically Undervalued After Upbeat FDA Meeting", "summary": "uniQure's stock appears significantly undervalued following a positive meeting with the FDA regarding its Huntington's Disease gene therapy, AMT-130. The FDA's willingness to accept Phase I/II study results for an \"accelerated approval\" application suggests potential approval, wh", "url": "https://www.barchart.com/story/news/2542163/uniqure-stock-looks-drastically-undervalued-after-upbeat-fda-meeting", "source_name": "Barchart.com", "published_at": "2026-06-18T17:39:46", "published_display": "18 Jun 2026 17:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UniQure's Approval Path Looks Stronger After US FDA Feedback, RBC Capital Markets Says", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/uniqure-apos-approval-path-looks-153710683.html", "source_name": "MT Newswires", "published_at": "2026-06-18T15:37:10+00:00", "published_display": "18 Jun 2026 15:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UniQure to seek approval of Huntington\u2019s gene therapy after FDA U-turn", "summary": "", "url": "https://finance.yahoo.com/m/388cee91-92f5-390c-9cd7-60ce2766c190/uniqure-to-seek-approval-of.html", "source_name": "Pharmaceutical Technology", "published_at": "2026-06-18T14:57:22+00:00", "published_display": "18 Jun 2026 14:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "uniQure stock rating reiterated at Buy by H.C. Wainwright on FDA update", "summary": "H.C. Wainwright reiterated a Buy rating and a $50.00 price target for uniQure (NASDAQ:QURE) after a regulatory update from the FDA regarding its Huntington's disease gene therapy, AMT-130. The FDA indicated that the 3-year analysis from the Phase 1/2 trial would be acceptable for", "url": "https://www.investing.com/news/analyst-ratings/uniqure-stock-rating-reiterated-at-buy-by-hc-wainwright-on-fda-update-93CH-4749658", "source_name": "Investing.com", "published_at": "2026-06-18T12:39:18", "published_display": "18 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 86, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "uniQure (QURE) Soars 78.4%: Is Further Upside Left in the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxQejEwWUZrX2tTT0ExLW92MWVPZzFmUEl3bkZMUDB4SmlucUxMd29ZMFNUdVl6WFdUaHJDb3Zfb3UyTjlqR3NxdGN1X2JBdG5POEh4dFI5clBtNHYtcThFZnRyVFpyTjBpOUZoQnZDRzJMaG5XZ0pUR2JqejFuQ3dOZ19DS0Fua2NON1ZjMkJleFM5QQ?oc=5", "source_name": "Market source", "published_at": "2026-06-18T11:30:00+00:00", "published_display": "18 Jun 2026 11:30", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] uniQure N.V. SEC Filing", "summary": "uniQure N.V. filed Form 144 on June 17, 2026, reporting the sale of ordinary shares through Citigroup Global Markets. The filing details the sale of 101,848 shares from vested PSUs/RSUs and 62,581 shares from a stock option exercise, both executed under Rule 10b5-1 plans. These t", "url": "https://www.stocktitan.net/sec-filings/QURE/144-uni-qure-n-v-sec-filing-1b7679d20488.html", "source_name": "Stock Titan", "published_at": "2026-06-18T00:18:49", "published_display": "18 Jun 2026 00:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UniQure Catapults Nearly 80% On A Gene Therapy Shock From The FDA", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPRk91RHZMQ2UwZmF1bE5qY0ZSTTA2M3VoSnNyaHZfaV9DanFCVXBURTFwZXBhbFEwQWRZdkU5aUh6bGpBX2o2WTJxRlZUcmoxajlCRENGSE1yczh1cG1zbnVHN3VsUk5zMmZxREw3T0RQV1k3d09Tc1NrTS1CN01HT0pZXy1tNDlYV3FQU1R2RnlXNlE4dWNuRQ?oc=5", "source_name": "Investor's Business Daily", "published_at": "2026-06-17T20:13:00+00:00", "published_display": "17 Jun 2026 20:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mizuho reiterates Outperform on uniQure stock, $35 target", "summary": "Mizuho has reiterated an Outperform rating and a $35 price target for uniQure (NASDAQ: QURE) following positive developments concerning its gene therapy for Huntington's disease, AMT-130. The FDA has agreed to accept 3-year Phase I/II results for an Accelerated BLA filing and exp", "url": "https://www.investing.com/news/analyst-ratings/mizuho-reiterates-outperform-on-uniqure-stock-35-target-93CH-4748041", "source_name": "Investing.com", "published_at": "2026-06-17T18:18:49", "published_display": "17 Jun 2026 18:18", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Goldman Sachs reiterates Neutral on uniQure stock after FDA meeting", "summary": "Goldman Sachs has reiterated a Neutral rating and a $46.00 price target for uniQure BV (NASDAQ:QURE) after the company announced plans to file for accelerated approval of its Huntington\u2019s disease gene therapy, AMT-130. The FDA agreed that three-year analysis from the Phase 1/2 st", "url": "https://www.investing.com/news/analyst-ratings/goldman-sachs-reiterates-neutral-on-uniqure-stock-after-fda-meeting-93CH-4748049", "source_name": "Investing.com", "published_at": "2026-06-17T18:09:33", "published_display": "17 Jun 2026 18:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UniQure to seek FDA approval for Huntington's disease gene therapy after previous clash with agency", "summary": "UniQure announced its intention to seek FDA approval for its experimental Huntington's disease gene therapy, following a recent meeting where the FDA indicated that three-year analysis from a Phase 1/2 study would support accelerated approval. This marks a significant reversal fr", "url": "https://www.cnbc.com/2026/06/17/huntingtons-disease-drugmaker-uniqure-to-seek-fda-ok-for-gene-therapy.html", "source_name": "CNBC", "published_at": "2026-06-17T18:03:00", "published_display": "17 Jun 2026 18:03", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stocks making the biggest moves midday: SpaceX, JPMorgan, UniQure, Intel, Figma, Nano Nuclear & more", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxQQ0o4eXNsSHlKd0tlQ0VBakhiNE9hWE1UZDgzSjVXcHJsa0ZwNm4yZXdZY1BYUXJNT0tlaWVtb3QyRXY4Qk5lRnQ5V0VIQ01IeHBUdE1lb0lrZ3dPT3RHdnZVSUtvVlVPVm5xOGJtLXlRZ0RhUHdtVF9jUFBNWmJMYU83WTNOMm54R0VMMEkwNDRpeXA0SkphSg?oc=5", "source_name": "CNBC", "published_at": "2026-06-17T16:37:52+00:00", "published_display": "17 Jun 2026 16:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Maintains UniQure NV(QURE.US) With Buy Rating, Maintains Target Price $50", "summary": "H.C. Wainwright has reiterated its Buy rating for UniQure NV (QURE.US), maintaining a target price of $50. This indicates the firm's continued confidence in the biotechnology company's future performance.", "url": "https://www.moomoo.com/news/post/71669392/hc-wainwright-maintains-uniqure-nv-qureus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-06-17T17:18:49", "published_display": "17 Jun 2026 17:18", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA Signals uniQure Huntington Gene Therapy Data Could Back Accelerated Approval", "summary": "The FDA has indicated that uniQure's three-year analysis from its Phase I/II study for Huntington's disease gene therapy, AMT-130, could support an accelerated approval pathway. This is a significant turnaround from earlier FDA advice that recommended against using this data as p", "url": "https://www.benzinga.com/news/health-care/26/06/53251736/fda-signals-uniqure-huntington-gene-therapy-data-could-back-accelerated-approval", "source_name": "Benzinga", "published_at": "2026-06-17T14:18:49", "published_display": "17 Jun 2026 14:18", "sentiment": "positive", "sentiment_pct": 87, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jabil Posts Upbeat Q3 Results, Joins Uniqure, Braiin And Other Big Stocks Moving Higher On Wednesday", "summary": "Jabil Inc. (NYSE: JBL) saw its shares jump 9.8% after reporting better-than-expected Q3 earnings and sales, with earnings of $3.16 per share and sales of $8.751 billion. The favorable report contributed to a generally higher trend in U.S. stocks, including the Dow Jones index. Se", "url": "https://www.benzinga.com/trading-ideas/movers/26/06/53250744/jabil-posts-upbeat-q3-results-joins-uniqure-braiin-and-other-big-stocks-moving-higher-on-wednesday", "source_name": "Benzinga", "published_at": "2026-06-17T14:09:33", "published_display": "17 Jun 2026 14:09", "sentiment": "positive", "sentiment_pct": 88, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Following dispute with FDA, UniQure is cleared to submit Huntington\u2019s treatment for approval", "summary": "UniQure has received clearance from the FDA to submit its experimental Huntington's disease treatment, AMT-130, for U.S. approval. This decision follows a reversal of the FDA's previous opposition, after the agency agreed that a three-year analysis of an early-stage study for the", "url": "https://www.statnews.com/2026/06/17/huntingtons-disease-uniqure-drug-fda-review/", "source_name": "STAT", "published_at": "2026-06-17T13:09:33", "published_display": "17 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "uniQure moves toward accelerated FDA approval for AMT-130", "summary": "uniQure announced that the FDA will accept three-year data from its AMT-130 Phase I/II trial in Huntington\u2019s disease as the basis for an accelerated approval Biologics License Application (BLA). The company plans to submit the BLA in Q3 2026 and has aligned with the FDA on a conf", "url": "https://www.tipranks.com/news/company-announcements/uniqure-moves-toward-accelerated-fda-approval-for-amt-130", "source_name": "TipRanks", "published_at": "2026-06-17T12:09:33", "published_display": "17 Jun 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UniQure Shares Soar After FDA Reversal on Its Huntington\u2019s Therapy", "summary": "UniQure NV shares surged following an announcement that the company can seek US approval for its Huntington's disease gene therapy without needing to conduct a new study. This decision by the FDA is seen as a significant reversal, indicating a potential relaxation of drug review ", "url": "https://www.bloomberg.com/news/articles/2026-06-17/uniqure-resolves-huntington-s-dispute-will-file-for-us-approval", "source_name": "Bloomberg", "published_at": "2026-06-17T11:27:00", "published_display": "17 Jun 2026 11:27", "sentiment": "positive", "sentiment_pct": 90, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA says 3-year trial data can support Huntington\u2019s treatment filing", "summary": "uniQure announced that the FDA has indicated its ~3-year Phase I/II study data for AMT-130 in Huntington's disease can serve as the primary basis for a Biologics License Application (BLA) for accelerated approval. The company plans to submit the BLA in Q3 2026 and will work with ", "url": "https://www.stocktitan.net/news/QURE/uni-qure-announces-plan-for-bla-submission-for-amt-130-in-huntington-jh4bm1tmrf3p.html", "source_name": "Stock Titan", "published_at": "2026-06-17T11:09:33", "published_display": "17 Jun 2026 11:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "uniQure Announces Plan for BLA Submission for AMT-130 in Huntington\u2019s Disease", "summary": "uniQure plans to submit a Biologics License Application (BLA) for accelerated approval of AMT-130 for Huntington's disease to the FDA in the third quarter of 2026. The FDA has agreed that the 3-year analysis from the Phase I/II study can serve as the primary basis for this BLA, c", "url": "https://www.globenewswire.com/news-release/2026/06/17/3313322/0/en/uniqure-announces-plan-for-bla-submission-for-amt-130-in-huntington-s-disease.html", "source_name": "GlobeNewswire", "published_at": "2026-06-17T07:05:00", "published_display": "17 Jun 2026 07:05", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "uniQure (QURE) investors approve share plan, charter and board at 2026 AGM", "summary": "uniQure N.V. shareholders approved all proposals at their 2026 annual general meeting, including amendments to the 2014 Share Incentive Plan to increase shares for equity compensation and modifications to the Articles of Association to reflect Dutch large company regime and incre", "url": "https://www.stocktitan.net/sec-filings/QURE/8-k-uni-qure-n-v-reports-material-event-0e42b4a6e15f.html", "source_name": "Stock Titan", "published_at": "2026-06-15T20:09:56", "published_display": "15 Jun 2026 20:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Don't Ignore The Insider Selling In uniQure", "summary": "uniQure's Chief Customer & Strategy Officer, Kylie O'Keefe, recently sold US$431k worth of stock, representing 13% of their holding. This was the largest insider sale in the past year, and no insider buying has been observed in the same period. While insider ownership is not part", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/dont-ignore-the-insider-selling-in-uniqure-1", "source_name": "Simply Wall Street", "published_at": "2026-06-15T10:09:56", "published_display": "15 Jun 2026 10:09", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did QURE Stock Almost Halve Pre-Market Today?", "summary": "uniQure (QURE) stock dropped nearly 45% pre-market after the FDA indicated that Phase I/II data for its Huntington\u2019s disease gene therapy, AMT-130, are insufficient for a marketing application. The FDA recommended a prospective, randomized, double-blind, sham-surgery-controlled s", "url": "https://stocktwits.com/news-articles/markets/equity/why-did-qure-stock-almost-halve-pre-market-today/cZd344CRIcD", "source_name": "Stocktwits", "published_at": "2026-06-13T21:40:52", "published_display": "13 Jun 2026 21:40", "sentiment": "negative", "sentiment_pct": 9, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "uniQure (QURE) director Leonard Post awarded RSUs, options and sells shares for taxes", "summary": "uniQure (QURE) director Leonard E. Post recently received equity compensation including 7,550 restricted share units and 13,980 stock options. He subsequently sold 1,993 Ordinary Shares at a weighted average price of $27.06, solely to cover estimated withholding taxes related to ", "url": "https://www.stocktitan.net/sec-filings/QURE/form-4-uni-qure-n-v-insider-trading-activity-b91b19c4fde6.html", "source_name": "Stock Titan", "published_at": "2026-06-13T10:09:27", "published_display": "13 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "uniQure (QURE) director receives RSUs, stock options and sells shares for taxes", "summary": "uniQure N.V. director Jeremy P. Springhorn reported receiving 7,550 restricted share units and 13,980 stock options on June 10, 2026, both vesting after one year. On June 11, 2026, he sold 1,993 Ordinary Shares at a weighted average price of $27.06 solely to cover withholding tax", "url": "https://www.stocktitan.net/sec-filings/QURE/form-4-uni-qure-n-v-insider-trading-activity-9be2cdf59b71.html", "source_name": "Stock Titan", "published_at": "2026-06-13T09:40:05", "published_display": "13 Jun 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tax-related share sale by uniQure (NASDAQ: QURE) chief customer officer", "summary": "uniQure N.V.'s Chief Customer & Strategy Officer, Kylie O\u2019Keefe, sold 15,936 ordinary shares on June 11, 2026, at a weighted average price of $27.06 per share. This sale was a non-discretionary transaction, executed automatically upon the vesting of restricted share units to cove", "url": "https://www.stocktitan.net/sec-filings/QURE/form-4-uni-qure-n-v-insider-trading-activity-749920d949a4.html", "source_name": "Stock Titan", "published_at": "2026-06-13T09:40:05", "published_display": "13 Jun 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RSU grant, options and tax sale for uniQure (NASDAQ: QURE) director", "summary": "uniQure N.V. director David D. Meek received 7,550 restricted share units and stock options for 13,980 Ordinary Shares. Concurrent with this, 1,993 Ordinary Shares were sold at a weighted average price of $27.06, solely to cover estimated withholding taxes upon RSU vesting, a non", "url": "https://www.stocktitan.net/sec-filings/QURE/form-4-uni-qure-n-v-insider-trading-activity-aeb1fcb58886.html", "source_name": "Stock Titan", "published_at": "2026-06-12T22:09:49", "published_display": "12 Jun 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Jack Kaye at uniQure (QURE) gets RSUs and options, sells shares for taxes", "summary": "uniQure (QURE) director Jack Kaye received 7,550 restricted share units (RSUs) and options for 13,980 Ordinary Shares. Following the RSU vesting, 1,993 shares were sold to cover tax obligations, not as a discretionary trade. Kaye directly holds 25,996 Ordinary Shares after these ", "url": "https://www.stocktitan.net/sec-filings/QURE/form-4-uni-qure-n-v-insider-trading-activity-a3405070dadd.html", "source_name": "Stock Titan", "published_at": "2026-06-12T21:09:49", "published_display": "12 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "uniQure N.V. stock (IL0011559904): Gene therapy player navigates strategic reset and cash conservati", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxPM3RlZU13WVdmd2pxa1pHajBrdXpXSlVQUDZoMGZISGhyd3c3R3dOdU5rZERxUnZNOTZydFBWakNoZEU4aHlCRE5oMVpvM2ZrYWxBV2RnS0N2MzZjZi16dExqeE1uelNzMXJ0blNiNTVKTXNZTzdIc2k4Q3MxQ25PZHl1NW9GYlVjSkw2MXhxS0xzMThPanFXZkRNQWhZb1VUVDA5aHoybXZyb3llYVpVU2VodHZOVUhYeVdfbE83eVVxeXpmTHdMcg?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RTW Investments and R. Wong report 2.59M shares in uniQure (NASDAQ: QURE)", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxNTDUyb0t2YVVOZU8tN2RYNmdSaWlJc2I0YkxVY29OY3pnY2Z4amxUMm15TWZTbnJxeWFBNnA4N1kwN0gzTGFJNkVRMkpiOTB1YXhZWlNVSnBYN2ZfdzdqekNEYmZ2eVppNDlibVRWZHBIVEhBbHM1ZHV6LVJBR3lUVGVVSU5TNnlobXYtLWtSQWM4SEZDcF9fLUk2a2daVlBNakdEbThsNHlLWnZ0UkJNTWpoLUM3MWp0a25EeURSLVM5aTBqUWc?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "uniQure N.V. (NASDAQ:QURE) Just Reported And Analysts Have Been Cutting Their Estimates", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UniQure (QURE) files Form 144: 45,000 shares, vested and exercised stock listed", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxQaURERlhodWFVN3JMMjFYU3BUSjcySW4xNERib1F4blJNYmx3aHZoaWVISVljU3FKTzg1enpEMDBzdFZIaC1QdEFKNVNNU0NjdmxIRGhpRV93OG50cWwzNGZaX0RxU0RpLXYxb0VzRjlOQzZNNG54WGRmVl9fS0ZJZVpjU1hsQjFKWWRrSmh5aWdab0E?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FMR LLC lists 1.74M UNIQURE shares (2.8%) \u2014 UNIQURE (NASDAQ: QURE)", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxOcWljWnVNeTVFaUt5RkRLZ0FqTEtINXVKN1hhMFk5Wng1NWRKV2hPUk1faXNvdnVtY2VpSVo1eHpNTVV6YVhJa2VvbW15MDdkZTFVNTNNTFJZSlhIaGV4NldTS1ExSXRRMXRGeUJhZTF6V3hKR3JUVFlXc0ZRRndOcmlGa2NoTml0V2JBRU9RV1FGcE5sY3JrYnBhZUQtRlpyYzY3X3pSM2lQVWhTb0VQQlhYSzYwekNrT3JsY001RFl0SE9NcEE?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNZXlTZHFHZVNxMktqZ0hVNURmdE1hUFpZZnlfdEVhMnVla2EyTWN6b2YwNkVhNllxUy1Bczl2a0ZUNk04Q3oyTEZSajdpMnFDVXJfRTlfLUdHQ05uS3FQZkhNWkJ0MDFENDJvRXR0ZGV1RDlYVmdWem96V29NeTg4YWRZWGNoMzM1emRoSExJbXdwZnJIWHpsYjVnT0FQVHZtUW5iVg?oc=5", "source_name": "Market source", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswJBVV95cUxNN3p5a01RVlNyaXFsUWFQZ080elFXWnhkV05tYnhVVGZxdV9vbHg5bWk1RDhiTnJiZkd6RF9jbXJUTk9Rejgzd1k4UWVISVhyOFBBT0tGR1lvZnE4aldsWE5NLXI5eXFRQkpGX095NlQxSktKcHpWQmc3RkhJblFzMFlWcVZNbnpBRmJiMmh6V1FpSm5qZklia2kweW56UUdIeDZ2YlFSSjVNYmtUMktKYjIxb1FTblBCU3ZYUWVFZ1hNRG92NVdPZzIxSUwzbVN3bkJuQTFBczRHTGxoeEZzNmo4MVpjX1NRVGREQTJYTDJudHBhS0tCcGRPTDhnZG9XRWg3aExmMkJ4YUpEZWJnckFhUjg0U24yOWk5QnB1NENiX2hOd3pGX1ItT0Y1SjdBVmxJ?oc=5", "source_name": "PR Newswire", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNIQURE N.V. (QURE) SHAREHOLDER ALERT Bernstein Liebhard", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAJBVV95cUxPNlcyN05zMW1mSVY0VHZfQS1oSmplSnN4ZUI0eUwtZkpiQkZnOUJsWTg1anNmVjVhanhFUXRvaF91NlU5WmlmdGFfai1tVFYxcWpHeHN2dGNBMV82SS12Y01uVGo4X0laOUtmbEdSMmFVOFVGYWktRi1RbkY4eWhEVnJSSlJ0djRoNWZoOEhmSDBpOC1RS3k4VElYdW9lSmwyOHJ4cF9Jb1paR3BQdzRGMVhJODk1cy01T3NKWmJwVTRjR0FFTnAxcVc0M0VES3hSWE5CLTRwbm50NUFQbUw5VlNQUFBabm8zTmRrVDBoMFUxRkdJVEdVcVJuWTE3bVpLc2ZRaXNadVQwNThD?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-19T07:00:00+00:00", "published_display": "19 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Just Happened with uniQure's Earnings and FDA Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxOOVQtZXN1VmRxMzZTdUZEOTZVOFhld2h5dVM2T1RSQ3hyYUp2M1hKNmFJenpKY181MThxamNaRFRFbEpQcW9zQjNrUWUxYm91U25kOWZYMktjZDhWU1VOdkQ0UDZfUE5CZ1lJWHJCTEtmXzhqQUJxTnBweW9PZk1ZN2J1a01NZWhIaUVUNmJFNjlROWNVaGFB?oc=5", "source_name": "Kavout", "published_at": "2026-03-02T16:07:38+00:00", "published_display": "02 Mar 2026 16:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "uniQure NV (QURE) Form 144: 16,499 RSUs vest; insider sold 6,217 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxOaUlZLWppUU45aUUwMEowbGlqU1dkYk8wM0JlVEpFa0E4dDFzUDZ5a2JOZTdDRWJ0dktMSklCTFFwX3lzempINFd4S0p0aWFnSm9WRnBtdFBzS0FJZHNlbVBCOWVGVjdPNWJBOS1NbndtdXNLbDFuYmhkd3I2SVplM2JwejNPZVhRc2R0T3MzR0hNWGM?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "uniQure starts $150M share sale, with $22.5M extra option", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQLVZuLWtBOUxpZS0wN2lPSkt4aFJaMFl6bDlXbjdSX05OVzdSZlYyUnY4LTJTR2xjQUlGRlR5eUsyMnUyTmU2Y0w2VjhFcXpISE9VTklabkpHc1F1X05BaXpXamh2WlpnWDRPRDB2ZEhIdkR0bDBJTjNvWFhQcmR4YUhTWmQzOE9yYi1yMzFscUJwZ1Ezd3RJLUxQWndnX0RUSmp3?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T20:03:47+00:00", "published_display": "22 Jun 2026 20:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "uniQure (QURE) CEO sells 206,100 shares and exercises stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxONzdteHo0QUw4b1VGYU1Ha1VYVEt4dHJSTmM2U1luT3BrVTdQOTF0VkNSNUhSbjQwTEtiNTdyeFZ2QnFsd29XRUdnN0N6V0hQWlpaU0JndUtTYnBsMzRmWmRUdmVDVi1qM1lTUDdOVVRJalVjTmNXbjhPbWxwTElMUGNxWUFZc1UtdTJSZXl4UU1JQ3ZnUXpxbDdxWW1fY2Q1YzZvbGkydjFMdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T12:31:27+00:00", "published_display": "22 Jun 2026 12:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "uniQure (QURE) director exercises 11,685 options, sells shares under 10b5-1", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPMjM1UnQ2UXdRbmtwLTBaZXhfUVBaMGNkYzU5OVc4dU9RVXdFeWFBTG0yTFBrclBrQ1MwLV9EMFlJWGZTR0dMTUl1MngwYkNwajFOVWNrQnVhSklnZ2g5QVh1aFZ6OHFfdHlrOHIzSnoxOGM2WjI0RHNROGg0VGpJMHVrY245c0ItdmZhWDRUT0xWU0lORzA2WkN1YTZqQndGN3BheWtuS0dTdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T12:05:31+00:00", "published_display": "22 Jun 2026 12:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "uniQure (QURE) Secures FDA Reversal for Huntington's Disease Gen", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNdkdiMjdkV2Y4UDI4eHBmVVE0RmEwQ1U5Zjg3dnF6ekNNdXNZWDlFckZ0aGR6RTJ3N3AwbjBxY2ZYRjQ2MG9BOWV3c2gtYjdzelZsbERONHRVQ2ZKRFVZR3ZiTlViQlpHb0lBMWVfak5pOHlzenBmSGxmWTZHU2pvR1VJQ3JsVW9fMTQ2UnVHdHpsNGxsY0YyaVFRQnhmNlNRUzJOQ3h0LUVUZDRySFE?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-22T11:29:05+00:00", "published_display": "22 Jun 2026 11:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "uniQure (QURE) director Jack Kaye sells shares after exercising stock options", "summary": "uniQure N.V. director Jack Kaye exercised stock options for 5,295 ordinary shares at $31.71 each and subsequently sold all of them in the open market for a weighted average price of $42.57. These transactions, which occurred on June 17, 2026, were conducted under a pre-arranged R", "url": "https://www.stocktitan.net/sec-filings/QURE/form-4-uni-qure-n-v-insider-trading-activity-744ddceff83c.html", "source_name": "Stock Titan", "published_at": "2026-06-22T12:09:37", "published_display": "22 Jun 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "uniQure (QURE) shows mixed but promising early AMT-260 MTLE results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPTExaUWhqd2lsVDFDZ3FBRU9hSVE4c0o1Vlhnbjc1ZVRoQ2Q0cHNYMXVONHIwS3VVQ1NLZDF2ZWl5d2pDc094YXFpM0RuV3hvRmlZUVZ2ajBtbUxIbVZtLWU1S0oyTm9FSmxwWTZVSFhaeDlrT0oyYXZnQTJIS0lBdW9BWEwzVHZMdEFPM2pCQ2dZbzdGZjMwYTBsVUYwLUpNZHRr?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T10:50:13+00:00", "published_display": "22 Jun 2026 10:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "uniQure reports preliminary AMT-260 Phase I/IIa low-dose results; 3 of 6 patients show 79\u2013100% seizure reduction", "summary": "uniQure announced preliminary six-month data from its AMT-260 Phase I/IIa trial, revealing that three out of six low-dose patients experienced significant seizure reductions of 79\u2013100%. The treatment was generally well-tolerated, with no serious adverse events reported and no imm", "url": "https://www.tradingview.com/news/tradingview:6ac619a43cdc0:0-uniqure-reports-preliminary-amt-260-phase-i-iia-low-dose-results-3-of-6-patients-show-79-100-seizure-reduction/", "source_name": "TradingView", "published_at": "2026-06-22T11:09:37", "published_display": "22 Jun 2026 11:09", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "QURE Stock Just Shot Up 8% - uniQure\u2019s Much-Talked-About Huntington\u2019s Disease Therapy Gets A UK Boost", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxNY0tPbUFINEhwMU9PRUNMMEVMNUF5UmplQTdhWTUtSU1hVnRQUUhzaklpdU5xdkN5aW9tdWpVR2EySDctYm5WQnJTc0NlTVdiOE93bkkyUzBVbERSZWoxdlhwY1NXRUVLVEVGbUo2VTg3VnFqU0d5U0cwOEJ2dFhpeTJxUlJ5clpNVldhbGc4SVdtS3dYUDlwalJoVGNtYVV4QXJ3NE9YamlzMzFpSlp0c24ydjIyRDJDamstRDdQM3pwc0NXZjh0aTNOZzI?oc=5", "source_name": "Stocktwits", "published_at": "2026-06-21T07:10:37+00:00", "published_display": "21 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "uniQure (QURE) Stock Could Be 12% Undervalued After FDA Backs AMT 130 Filing Path", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-20T13:28:27+00:00", "published_display": "20 Jun 2026 13:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "QURE Soars as FDA Backs AMT-130 Data for Accelerated Approval", "summary": "uniQure (QURE) saw its shares jump significantly after the FDA indicated that three-year data from its phase I/II study on AMT-130, a gene therapy for Huntington's disease, could support an accelerated approval BLA. This news provides relief to investors following a previous regu", "url": "https://www.tradingview.com/news/zacks:2dd42ff47094b:0-qure-soars-as-fda-backs-amt-130-data-for-accelerated-approval/", "source_name": "TradingView", "published_at": "2026-06-19T18:40:52", "published_display": "19 Jun 2026 18:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/uniqure-announces-preliminary-data-first-110500802.html", "source_name": "GlobeNewswire", "published_at": "2026-06-19T11:05:00+00:00", "published_display": "19 Jun 2026 11:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "uniQure (QURE) Stock Sees Fair Value Lift As AMT 130 BLA Plans Rework Risk", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNbTZNSVR5M05lNllZY1RYMnhtcVdTbVNMZUpURjFJWTJnNE85NHEyR0xpQmJLd2I3Z3daNV9xNEMxdE1mSTY2RGxlXzVzYjA2WXVhXzNPaEZKZEsyVEFUUDd0UHV1TDRZY1JBalFVQUNMakxKUER1ZjNNTTVjWnU5TmNJMUZld3RzdTAxT1JQVm8ySi04eDRQYw?oc=5", "source_name": "Market source", "published_at": "2026-06-19T10:11:19+00:00", "published_display": "19 Jun 2026 10:11", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "uniQure\u2019s epilepsy gene therapy showed seizure drops in 3 patients", "summary": "uniQure announced preliminary six-month data from the first, low-dose cohort of its Phase I/IIa trial for AMT-260, an investigational gene therapy for refractory mesial temporal lobe epilepsy. Three of six patients showed significant reductions (79%-100%) in disabling seizures, w", "url": "https://www.stocktitan.net/news/QURE/uni-qure-announces-preliminary-data-on-the-first-cohort-in-the-phase-z3qytxeiakcc.html", "source_name": "Stock Titan", "published_at": "2026-06-19T11:04:46", "published_display": "19 Jun 2026 11:04", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "uniQure Announces Preliminary Data on the First Cohort in", "summary": "uniQure announced preliminary six-month data from the first cohort of its Phase I/IIa trial for AMT-260, an investigational gene therapy for refractory mesial temporal lobe epilepsy. Three of six patients in the low-dose cohort experienced significant reductions in seizures, with", "url": "https://www.globenewswire.com/news-release/2026/06/19/3314701/0/en/uniqure-announces-preliminary-data-on-the-first-cohort-in-the-phase-i-iia-clinical-trial-of-amt-260-in-refractory-mesial-temporal-lobe-epilepsy.html", "source_name": "GlobeNewswire", "published_at": "2026-06-19T11:04:46", "published_display": "19 Jun 2026 11:04", "sentiment": "positive", "sentiment_pct": 65, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "uniQure (QURE) Stock Could Be 49% Undervalued After FDA AMT 130 Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxQN05oSVcxSkZDczlPN19CSTI0dzRCX1hRVVFmYmlVRGFhc09OTXFsRktZRUlfNWNWR1hKUWVyNGVqZlBDREl2Z3J6bnZCZVRLdzktRlZnWnVZaU5NWDhKWXFSb2ttUmJ0TVN6RHdVUGptb0xBZnlTb25rNnQwTG94ZHQyakdRMExjV2h1TmF2aGdnSEFBU1pN?oc=5", "source_name": "Market source", "published_at": "2026-06-19T06:15:10+00:00", "published_display": "19 Jun 2026 06:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "uniQure (QURE) Is Up 67.9% After FDA Backs AMT-130 Data For Accelerated Approval Path", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/uniqure-qure-67-9-fda-050753380.html", "source_name": "Simply Wall St.", "published_at": "2026-06-19T05:07:53+00:00", "published_display": "19 Jun 2026 05:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Quick Look at Today's Ratings for UniQure NV(QURE.US), With a Forecast Between $46 to $70", "summary": "This article provides an overview of recent analyst ratings for uniQure NV (QURE.US), highlighting that analysts have set price targets ranging from $46 to $70. The consensus among analysts suggests a positive outlook for the company's stock performance.", "url": "https://www.moomoo.com/news/post/71734507/a-quick-look-at-today-s-ratings-for-uniqure-nv", "source_name": "Moomoo", "published_at": "2026-06-19T00:10:39", "published_display": "19 Jun 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "uniQure N.V. (NASDAQ: QURE) insider sells 164,429 shares across June filings", "summary": "uniQure N.V. (NASDAQ: QURE) insider Matthew C. Kapusta has reported planned and completed sales of 164,429 ordinary shares across various June filings. This includes recent market sales on June 17 and June 18, 2026, totaling over $7.2 million, as well as scheduled dispositions of", "url": "https://www.stocktitan.net/sec-filings/QURE/144-uni-qure-n-v-sec-filing-fe11e58baabc.html", "source_name": "Stock Titan", "published_at": "2026-06-18T21:39:18", "published_display": "18 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "uniQure Stock Looks Drastically Undervalued After Upbeat FDA Meeting", "summary": "uniQure's stock appears significantly undervalued following a positive meeting with the FDA regarding its Huntington's Disease gene therapy, AMT-130. The FDA's willingness to accept Phase I/II study results for an \"accelerated approval\" application suggests potential approval, wh", "url": "https://www.barchart.com/story/news/2542163/uniqure-stock-looks-drastically-undervalued-after-upbeat-fda-meeting", "source_name": "Barchart.com", "published_at": "2026-06-18T17:39:46", "published_display": "18 Jun 2026 17:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UniQure's Approval Path Looks Stronger After US FDA Feedback, RBC Capital Markets Says", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/uniqure-apos-approval-path-looks-153710683.html", "source_name": "MT Newswires", "published_at": "2026-06-18T15:37:10+00:00", "published_display": "18 Jun 2026 15:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UniQure to seek approval of Huntington\u2019s gene therapy after FDA U-turn", "summary": "", "url": "https://finance.yahoo.com/m/388cee91-92f5-390c-9cd7-60ce2766c190/uniqure-to-seek-approval-of.html", "source_name": "Pharmaceutical Technology", "published_at": "2026-06-18T14:57:22+00:00", "published_display": "18 Jun 2026 14:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "uniQure stock rating reiterated at Buy by H.C. Wainwright on FDA update", "summary": "H.C. Wainwright reiterated a Buy rating and a $50.00 price target for uniQure (NASDAQ:QURE) after a regulatory update from the FDA regarding its Huntington's disease gene therapy, AMT-130. The FDA indicated that the 3-year analysis from the Phase 1/2 trial would be acceptable for", "url": "https://www.investing.com/news/analyst-ratings/uniqure-stock-rating-reiterated-at-buy-by-hc-wainwright-on-fda-update-93CH-4749658", "source_name": "Investing.com", "published_at": "2026-06-18T12:39:18", "published_display": "18 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 86, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "uniQure (QURE) Soars 78.4%: Is Further Upside Left in the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxQejEwWUZrX2tTT0ExLW92MWVPZzFmUEl3bkZMUDB4SmlucUxMd29ZMFNUdVl6WFdUaHJDb3Zfb3UyTjlqR3NxdGN1X2JBdG5POEh4dFI5clBtNHYtcThFZnRyVFpyTjBpOUZoQnZDRzJMaG5XZ0pUR2JqejFuQ3dOZ19DS0Fua2NON1ZjMkJleFM5QQ?oc=5", "source_name": "Market source", "published_at": "2026-06-18T11:30:00+00:00", "published_display": "18 Jun 2026 11:30", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] uniQure N.V. SEC Filing", "summary": "uniQure N.V. filed Form 144 on June 17, 2026, reporting the sale of ordinary shares through Citigroup Global Markets. The filing details the sale of 101,848 shares from vested PSUs/RSUs and 62,581 shares from a stock option exercise, both executed under Rule 10b5-1 plans. These t", "url": "https://www.stocktitan.net/sec-filings/QURE/144-uni-qure-n-v-sec-filing-1b7679d20488.html", "source_name": "Stock Titan", "published_at": "2026-06-18T00:18:49", "published_display": "18 Jun 2026 00:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UniQure Catapults Nearly 80% On A Gene Therapy Shock From The FDA", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPRk91RHZMQ2UwZmF1bE5qY0ZSTTA2M3VoSnNyaHZfaV9DanFCVXBURTFwZXBhbFEwQWRZdkU5aUh6bGpBX2o2WTJxRlZUcmoxajlCRENGSE1yczh1cG1zbnVHN3VsUk5zMmZxREw3T0RQV1k3d09Tc1NrTS1CN01HT0pZXy1tNDlYV3FQU1R2RnlXNlE4dWNuRQ?oc=5", "source_name": "Investor's Business Daily", "published_at": "2026-06-17T20:13:00+00:00", "published_display": "17 Jun 2026 20:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mizuho reiterates Outperform on uniQure stock, $35 target", "summary": "Mizuho has reiterated an Outperform rating and a $35 price target for uniQure (NASDAQ: QURE) following positive developments concerning its gene therapy for Huntington's disease, AMT-130. The FDA has agreed to accept 3-year Phase I/II results for an Accelerated BLA filing and exp", "url": "https://www.investing.com/news/analyst-ratings/mizuho-reiterates-outperform-on-uniqure-stock-35-target-93CH-4748041", "source_name": "Investing.com", "published_at": "2026-06-17T18:18:49", "published_display": "17 Jun 2026 18:18", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Goldman Sachs reiterates Neutral on uniQure stock after FDA meeting", "summary": "Goldman Sachs has reiterated a Neutral rating and a $46.00 price target for uniQure BV (NASDAQ:QURE) after the company announced plans to file for accelerated approval of its Huntington\u2019s disease gene therapy, AMT-130. The FDA agreed that three-year analysis from the Phase 1/2 st", "url": "https://www.investing.com/news/analyst-ratings/goldman-sachs-reiterates-neutral-on-uniqure-stock-after-fda-meeting-93CH-4748049", "source_name": "Investing.com", "published_at": "2026-06-17T18:09:33", "published_display": "17 Jun 2026 18:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UniQure to seek FDA approval for Huntington's disease gene therapy after previous clash with agency", "summary": "UniQure announced its intention to seek FDA approval for its experimental Huntington's disease gene therapy, following a recent meeting where the FDA indicated that three-year analysis from a Phase 1/2 study would support accelerated approval. This marks a significant reversal fr", "url": "https://www.cnbc.com/2026/06/17/huntingtons-disease-drugmaker-uniqure-to-seek-fda-ok-for-gene-therapy.html", "source_name": "CNBC", "published_at": "2026-06-17T18:03:00", "published_display": "17 Jun 2026 18:03", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stocks making the biggest moves midday: SpaceX, JPMorgan, UniQure, Intel, Figma, Nano Nuclear & more", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxQQ0o4eXNsSHlKd0tlQ0VBakhiNE9hWE1UZDgzSjVXcHJsa0ZwNm4yZXdZY1BYUXJNT0tlaWVtb3QyRXY4Qk5lRnQ5V0VIQ01IeHBUdE1lb0lrZ3dPT3RHdnZVSUtvVlVPVm5xOGJtLXlRZ0RhUHdtVF9jUFBNWmJMYU83WTNOMm54R0VMMEkwNDRpeXA0SkphSg?oc=5", "source_name": "CNBC", "published_at": "2026-06-17T16:37:52+00:00", "published_display": "17 Jun 2026 16:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Maintains UniQure NV(QURE.US) With Buy Rating, Maintains Target Price $50", "summary": "H.C. Wainwright has reiterated its Buy rating for UniQure NV (QURE.US), maintaining a target price of $50. This indicates the firm's continued confidence in the biotechnology company's future performance.", "url": "https://www.moomoo.com/news/post/71669392/hc-wainwright-maintains-uniqure-nv-qureus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-06-17T17:18:49", "published_display": "17 Jun 2026 17:18", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA Signals uniQure Huntington Gene Therapy Data Could Back Accelerated Approval", "summary": "The FDA has indicated that uniQure's three-year analysis from its Phase I/II study for Huntington's disease gene therapy, AMT-130, could support an accelerated approval pathway. This is a significant turnaround from earlier FDA advice that recommended against using this data as p", "url": "https://www.benzinga.com/news/health-care/26/06/53251736/fda-signals-uniqure-huntington-gene-therapy-data-could-back-accelerated-approval", "source_name": "Benzinga", "published_at": "2026-06-17T14:18:49", "published_display": "17 Jun 2026 14:18", "sentiment": "positive", "sentiment_pct": 87, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jabil Posts Upbeat Q3 Results, Joins Uniqure, Braiin And Other Big Stocks Moving Higher On Wednesday", "summary": "Jabil Inc. (NYSE: JBL) saw its shares jump 9.8% after reporting better-than-expected Q3 earnings and sales, with earnings of $3.16 per share and sales of $8.751 billion. The favorable report contributed to a generally higher trend in U.S. stocks, including the Dow Jones index. Se", "url": "https://www.benzinga.com/trading-ideas/movers/26/06/53250744/jabil-posts-upbeat-q3-results-joins-uniqure-braiin-and-other-big-stocks-moving-higher-on-wednesday", "source_name": "Benzinga", "published_at": "2026-06-17T14:09:33", "published_display": "17 Jun 2026 14:09", "sentiment": "positive", "sentiment_pct": 88, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Following dispute with FDA, UniQure is cleared to submit Huntington\u2019s treatment for approval", "summary": "UniQure has received clearance from the FDA to submit its experimental Huntington's disease treatment, AMT-130, for U.S. approval. This decision follows a reversal of the FDA's previous opposition, after the agency agreed that a three-year analysis of an early-stage study for the", "url": "https://www.statnews.com/2026/06/17/huntingtons-disease-uniqure-drug-fda-review/", "source_name": "STAT", "published_at": "2026-06-17T13:09:33", "published_display": "17 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "uniQure moves toward accelerated FDA approval for AMT-130", "summary": "uniQure announced that the FDA will accept three-year data from its AMT-130 Phase I/II trial in Huntington\u2019s disease as the basis for an accelerated approval Biologics License Application (BLA). The company plans to submit the BLA in Q3 2026 and has aligned with the FDA on a conf", "url": "https://www.tipranks.com/news/company-announcements/uniqure-moves-toward-accelerated-fda-approval-for-amt-130", "source_name": "TipRanks", "published_at": "2026-06-17T12:09:33", "published_display": "17 Jun 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UniQure Shares Soar After FDA Reversal on Its Huntington\u2019s Therapy", "summary": "UniQure NV shares surged following an announcement that the company can seek US approval for its Huntington's disease gene therapy without needing to conduct a new study. This decision by the FDA is seen as a significant reversal, indicating a potential relaxation of drug review ", "url": "https://www.bloomberg.com/news/articles/2026-06-17/uniqure-resolves-huntington-s-dispute-will-file-for-us-approval", "source_name": "Bloomberg", "published_at": "2026-06-17T11:27:00", "published_display": "17 Jun 2026 11:27", "sentiment": "positive", "sentiment_pct": 90, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA says 3-year trial data can support Huntington\u2019s treatment filing", "summary": "uniQure announced that the FDA has indicated its ~3-year Phase I/II study data for AMT-130 in Huntington's disease can serve as the primary basis for a Biologics License Application (BLA) for accelerated approval. The company plans to submit the BLA in Q3 2026 and will work with ", "url": "https://www.stocktitan.net/news/QURE/uni-qure-announces-plan-for-bla-submission-for-amt-130-in-huntington-jh4bm1tmrf3p.html", "source_name": "Stock Titan", "published_at": "2026-06-17T11:09:33", "published_display": "17 Jun 2026 11:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "uniQure Announces Plan for BLA Submission for AMT-130 in Huntington\u2019s Disease", "summary": "uniQure plans to submit a Biologics License Application (BLA) for accelerated approval of AMT-130 for Huntington's disease to the FDA in the third quarter of 2026. The FDA has agreed that the 3-year analysis from the Phase I/II study can serve as the primary basis for this BLA, c", "url": "https://www.globenewswire.com/news-release/2026/06/17/3313322/0/en/uniqure-announces-plan-for-bla-submission-for-amt-130-in-huntington-s-disease.html", "source_name": "GlobeNewswire", "published_at": "2026-06-17T07:05:00", "published_display": "17 Jun 2026 07:05", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "uniQure (QURE) investors approve share plan, charter and board at 2026 AGM", "summary": "uniQure N.V. shareholders approved all proposals at their 2026 annual general meeting, including amendments to the 2014 Share Incentive Plan to increase shares for equity compensation and modifications to the Articles of Association to reflect Dutch large company regime and incre", "url": "https://www.stocktitan.net/sec-filings/QURE/8-k-uni-qure-n-v-reports-material-event-0e42b4a6e15f.html", "source_name": "Stock Titan", "published_at": "2026-06-15T20:09:56", "published_display": "15 Jun 2026 20:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Don't Ignore The Insider Selling In uniQure", "summary": "uniQure's Chief Customer & Strategy Officer, Kylie O'Keefe, recently sold US$431k worth of stock, representing 13% of their holding. This was the largest insider sale in the past year, and no insider buying has been observed in the same period. While insider ownership is not part", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/dont-ignore-the-insider-selling-in-uniqure-1", "source_name": "Simply Wall Street", "published_at": "2026-06-15T10:09:56", "published_display": "15 Jun 2026 10:09", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did QURE Stock Almost Halve Pre-Market Today?", "summary": "uniQure (QURE) stock dropped nearly 45% pre-market after the FDA indicated that Phase I/II data for its Huntington\u2019s disease gene therapy, AMT-130, are insufficient for a marketing application. The FDA recommended a prospective, randomized, double-blind, sham-surgery-controlled s", "url": "https://stocktwits.com/news-articles/markets/equity/why-did-qure-stock-almost-halve-pre-market-today/cZd344CRIcD", "source_name": "Stocktwits", "published_at": "2026-06-13T21:40:52", "published_display": "13 Jun 2026 21:40", "sentiment": "negative", "sentiment_pct": 9, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "uniQure (QURE) director Leonard Post awarded RSUs, options and sells shares for taxes", "summary": "uniQure (QURE) director Leonard E. Post recently received equity compensation including 7,550 restricted share units and 13,980 stock options. He subsequently sold 1,993 Ordinary Shares at a weighted average price of $27.06, solely to cover estimated withholding taxes related to ", "url": "https://www.stocktitan.net/sec-filings/QURE/form-4-uni-qure-n-v-insider-trading-activity-b91b19c4fde6.html", "source_name": "Stock Titan", "published_at": "2026-06-13T10:09:27", "published_display": "13 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "uniQure (QURE) director receives RSUs, stock options and sells shares for taxes", "summary": "uniQure N.V. director Jeremy P. Springhorn reported receiving 7,550 restricted share units and 13,980 stock options on June 10, 2026, both vesting after one year. On June 11, 2026, he sold 1,993 Ordinary Shares at a weighted average price of $27.06 solely to cover withholding tax", "url": "https://www.stocktitan.net/sec-filings/QURE/form-4-uni-qure-n-v-insider-trading-activity-9be2cdf59b71.html", "source_name": "Stock Titan", "published_at": "2026-06-13T09:40:05", "published_display": "13 Jun 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tax-related share sale by uniQure (NASDAQ: QURE) chief customer officer", "summary": "uniQure N.V.'s Chief Customer & Strategy Officer, Kylie O\u2019Keefe, sold 15,936 ordinary shares on June 11, 2026, at a weighted average price of $27.06 per share. This sale was a non-discretionary transaction, executed automatically upon the vesting of restricted share units to cove", "url": "https://www.stocktitan.net/sec-filings/QURE/form-4-uni-qure-n-v-insider-trading-activity-749920d949a4.html", "source_name": "Stock Titan", "published_at": "2026-06-13T09:40:05", "published_display": "13 Jun 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RSU grant, options and tax sale for uniQure (NASDAQ: QURE) director", "summary": "uniQure N.V. director David D. Meek received 7,550 restricted share units and stock options for 13,980 Ordinary Shares. Concurrent with this, 1,993 Ordinary Shares were sold at a weighted average price of $27.06, solely to cover estimated withholding taxes upon RSU vesting, a non", "url": "https://www.stocktitan.net/sec-filings/QURE/form-4-uni-qure-n-v-insider-trading-activity-aeb1fcb58886.html", "source_name": "Stock Titan", "published_at": "2026-06-12T22:09:49", "published_display": "12 Jun 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Jack Kaye at uniQure (QURE) gets RSUs and options, sells shares for taxes", "summary": "uniQure (QURE) director Jack Kaye received 7,550 restricted share units (RSUs) and options for 13,980 Ordinary Shares. Following the RSU vesting, 1,993 shares were sold to cover tax obligations, not as a discretionary trade. Kaye directly holds 25,996 Ordinary Shares after these ", "url": "https://www.stocktitan.net/sec-filings/QURE/form-4-uni-qure-n-v-insider-trading-activity-a3405070dadd.html", "source_name": "Stock Titan", "published_at": "2026-06-12T21:09:49", "published_display": "12 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "uniQure N.V. stock (IL0011559904): Gene therapy player navigates strategic reset and cash conservati", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxPM3RlZU13WVdmd2pxa1pHajBrdXpXSlVQUDZoMGZISGhyd3c3R3dOdU5rZERxUnZNOTZydFBWakNoZEU4aHlCRE5oMVpvM2ZrYWxBV2RnS0N2MzZjZi16dExqeE1uelNzMXJ0blNiNTVKTXNZTzdIc2k4Q3MxQ25PZHl1NW9GYlVjSkw2MXhxS0xzMThPanFXZkRNQWhZb1VUVDA5aHoybXZyb3llYVpVU2VodHZOVUhYeVdfbE83eVVxeXpmTHdMcg?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RTW Investments and R. Wong report 2.59M shares in uniQure (NASDAQ: QURE)", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxNTDUyb0t2YVVOZU8tN2RYNmdSaWlJc2I0YkxVY29OY3pnY2Z4amxUMm15TWZTbnJxeWFBNnA4N1kwN0gzTGFJNkVRMkpiOTB1YXhZWlNVSnBYN2ZfdzdqekNEYmZ2eVppNDlibVRWZHBIVEhBbHM1ZHV6LVJBR3lUVGVVSU5TNnlobXYtLWtSQWM4SEZDcF9fLUk2a2daVlBNakdEbThsNHlLWnZ0UkJNTWpoLUM3MWp0a25EeURSLVM5aTBqUWc?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "uniQure N.V. (NASDAQ:QURE) Just Reported And Analysts Have Been Cutting Their Estimates", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UniQure (QURE) files Form 144: 45,000 shares, vested and exercised stock listed", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxQaURERlhodWFVN3JMMjFYU3BUSjcySW4xNERib1F4blJNYmx3aHZoaWVISVljU3FKTzg1enpEMDBzdFZIaC1QdEFKNVNNU0NjdmxIRGhpRV93OG50cWwzNGZaX0RxU0RpLXYxb0VzRjlOQzZNNG54WGRmVl9fS0ZJZVpjU1hsQjFKWWRrSmh5aWdab0E?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FMR LLC lists 1.74M UNIQURE shares (2.8%) \u2014 UNIQURE (NASDAQ: QURE)", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxOcWljWnVNeTVFaUt5RkRLZ0FqTEtINXVKN1hhMFk5Wng1NWRKV2hPUk1faXNvdnVtY2VpSVo1eHpNTVV6YVhJa2VvbW15MDdkZTFVNTNNTFJZSlhIaGV4NldTS1ExSXRRMXRGeUJhZTF6V3hKR3JUVFlXc0ZRRndOcmlGa2NoTml0V2JBRU9RV1FGcE5sY3JrYnBhZUQtRlpyYzY3X3pSM2lQVWhTb0VQQlhYSzYwekNrT3JsY001RFl0SE9NcEE?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswJBVV95cUxNN3p5a01RVlNyaXFsUWFQZ080elFXWnhkV05tYnhVVGZxdV9vbHg5bWk1RDhiTnJiZkd6RF9jbXJUTk9Rejgzd1k4UWVISVhyOFBBT0tGR1lvZnE4aldsWE5NLXI5eXFRQkpGX095NlQxSktKcHpWQmc3RkhJblFzMFlWcVZNbnpBRmJiMmh6V1FpSm5qZklia2kweW56UUdIeDZ2YlFSSjVNYmtUMktKYjIxb1FTblBCU3ZYUWVFZ1hNRG92NVdPZzIxSUwzbVN3bkJuQTFBczRHTGxoeEZzNmo4MVpjX1NRVGREQTJYTDJudHBhS0tCcGRPTDhnZG9XRWg3aExmMkJ4YUpEZWJnckFhUjg0U24yOWk5QnB1NENiX2hOd3pGX1ItT0Y1SjdBVmxJ?oc=5", "source_name": "PR Newswire", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNIQURE N.V. (QURE) SHAREHOLDER ALERT Bernstein Liebhard", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAJBVV95cUxPNlcyN05zMW1mSVY0VHZfQS1oSmplSnN4ZUI0eUwtZkpiQkZnOUJsWTg1anNmVjVhanhFUXRvaF91NlU5WmlmdGFfai1tVFYxcWpHeHN2dGNBMV82SS12Y01uVGo4X0laOUtmbEdSMmFVOFVGYWktRi1RbkY4eWhEVnJSSlJ0djRoNWZoOEhmSDBpOC1RS3k4VElYdW9lSmwyOHJ4cF9Jb1paR3BQdzRGMVhJODk1cy01T3NKWmJwVTRjR0FFTnAxcVc0M0VES3hSWE5CLTRwbm50NUFQbUw5VlNQUFBabm8zTmRrVDBoMFUxRkdJVEdVcVJuWTE3bVpLc2ZRaXNadVQwNThD?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-19T07:00:00+00:00", "published_display": "19 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Just Happened with uniQure's Earnings and FDA Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxOOVQtZXN1VmRxMzZTdUZEOTZVOFhld2h5dVM2T1RSQ3hyYUp2M1hKNmFJenpKY181MThxamNaRFRFbEpQcW9zQjNrUWUxYm91U25kOWZYMktjZDhWU1VOdkQ0UDZfUE5CZ1lJWHJCTEtmXzhqQUJxTnBweW9PZk1ZN2J1a01NZWhIaUVUNmJFNjlROWNVaGFB?oc=5", "source_name": "Kavout", "published_at": "2026-03-02T16:07:38+00:00", "published_display": "02 Mar 2026 16:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "uniQure NV (QURE) Form 144: 16,499 RSUs vest; insider sold 6,217 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxOaUlZLWppUU45aUUwMEowbGlqU1dkYk8wM0JlVEpFa0E4dDFzUDZ5a2JOZTdDRWJ0dktMSklCTFFwX3lzempINFd4S0p0aWFnSm9WRnBtdFBzS0FJZHNlbVBCOWVGVjdPNWJBOS1NbndtdXNLbDFuYmhkd3I2SVplM2JwejNPZVhRc2R0T3MzR0hNWGM?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNZXlTZHFHZVNxMktqZ0hVNURmdE1hUFpZZnlfdEVhMnVla2EyTWN6b2YwNkVhNllxUy1Bczl2a0ZUNk04Q3oyTEZSajdpMnFDVXJfRTlfLUdHQ05uS3FQZkhNWkJ0MDFENDJvRXR0ZGV1RDlYVmdWem96V29NeTg4YWRZWGNoMzM1emRoSExJbXdwZnJIWHpsYjVnT0FQVHZtUW5iVg?oc=5", "source_name": "Market source", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 109, "total_relevant": 67, "sentiment_summary": {"positive": 20, "negative": 7, "neutral": 40, "score": 56, "total": 67, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 19.05, "count": 34}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 7.85, "count": 13}, {"event": "earnings", "label": "Earnings", "weight": 6.74, "count": 14}, {"event": "analyst", "label": "Analyst action", "weight": 2.2, "count": 4}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 20, "negative_events": 7}, "market_context": {"has_market_context": true, "latest_close": 46.29, "latest_week": "2026-06-19", "one_week_move": 67.9, "four_week_move": 91.4, "twelve_week_move": 213.4, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.078712, "market_dynamics_buy_signal": false, "relative_strength": 52.590681, "fair_value_gap": 226.5, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "negative", "expectation_probability": 43.6139, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+67.9% over one week, +91.4% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 64, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 19}, {"label": "Market source", "count": 8}, {"label": "GlobeNewswire", "count": 4}, {"label": "simplywall.st", "count": 3}, {"label": "Investing.com", "count": 3}, {"label": "TradingView", "count": 2}, {"label": "Stocktwits", "count": 2}, {"label": "Moomoo", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 60}, {"label": "Industry context", "count": 7}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 34}, {"label": "Earnings", "count": 14}, {"label": "Regulatory and legal", "count": 13}, {"label": "Analyst action", "count": 4}, {"label": "Guidance", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "56/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "60", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "3", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+67.9% over one week, +91.4% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "uniQure starts $150M share sale, with $22.5M extra option"}], "updated_at": "2026-06-22T20:04:47.420097+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}